Alcon Inc. Ordinary Shares
ALCAlcon Inc. is a global leader in eye care, specializing in the development, manufacturing, and marketing of ophthalmic products including surgical devices, eye care, and contact lenses. Founded in Switzerland, the company has a strong presence worldwide and is known for its innovations in vision care and eye health solutions.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| May 7, 2026 | $0.28 | 2026-05-06 | 2026-05-06 |
| May 15, 2025 | $0.28 | 2025-05-14 | 2025-05-14 |
| May 16, 2024 | $0.24 | 2024-05-14 | 2024-05-15 |
| May 12, 2023 | $0.21 | 2023-05-10 | 2023-05-11 |
| May 5, 2022 | $0.20 | 2022-05-03 | 2022-05-04 |
Dividends Summary
- Consistent Payer: Alcon Inc. Ordinary Shares has rewarded shareholders with 6 dividend payments over the past 5 years.
- Total Returned Value: Investors who held ALC shares during this period received a total of $1.31 per share in dividend income.
- Latest Payout: The most recent dividend of $0.28/share was paid 72 days ago, on May 7, 2026.
- Yield & Schedule: ALC currently pays dividends yearly with an annual yield of 0.40%.
- Dividend Growth: Since 2021, the dividend payout has grown by 180.0%, from $0.10 to $0.28.
- Dividend Reliability: ALC has maintained or increased its dividend for 6 consecutive payments.
Company News
The global ophthalmology devices market is projected to grow from $56.61 billion in 2025 to $99.22 billion by 2030, with a CAGR of 11.9%. Key growth drivers include rising demand for minimally invasive surgeries, an aging population, increased eye disorders, and innovation in precision surgical tools. Leading companies include EssilorLuxottica, A...
Abbott Laboratories and Glaukos represent two contrasting healthcare investment strategies: Abbott offers stability through diversification, strong profitability, and recent acquisitions like Exact Sciences, while Glaukos provides high-growth potential in specialized ophthalmic treatments with innovative products like iDose and Epioxa. Abbott tra...
The National Advertising Division ruled that Johnson & Johnson Vision Care's claim 'MAX comfort. MAX clarity.' for ACUVUE® Oasys Max 1-Day contact lenses is supported when compared to Oasys 1-Day. However, NAD recommended discontinuation or modification of superiority claims versus DAILIES TOTAL1® and '2X' comparative claims, finding insufficie...
Alcon has terminated its merger agreement with LENSAR, a laser solutions company, after prolonged regulatory review by the Federal Trade Commission made the deal unattractive. The acquisition, originally agreed upon in March 2025 at $14.00 per share, faced extended delays and opposition. LENSAR shares plunged 25.44% in premarket trading to $7.65,...
DallasCISO held its 2026 ORBIE Awards ceremony recognizing seven leading CISOs for exceptional cybersecurity leadership and business transformation. Award winners included executives from Alcon, Infor, Sammons Financial Group, National Veterinary Associates, DFW International Airport, MRO Corp, and Okta. The event brought together over 250 indust...
